Skip to content

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
HHS Expands Mental Health
Health

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

October 4, 2026 Evan Vega
Ebola Worker Evacuated Congo
Health

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

October 3, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
HHS Expands Mental Health
Health

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

October 4, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
HHS Expands Mental Health
Health

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

October 4, 2026 Evan Vega
Ebola Worker Evacuated Congo
Health

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

October 3, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
HHS Expands Mental Health
Health

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

October 4, 2026 Evan Vega
Amivantamab approved for HNSCC
Health

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

November 7, 2026 Evan Vega

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

FDA approves Rybrevant Faspro
Health

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

November 7, 2026 Evan Vega
FDA Approves Pirtobrutinib Treatment
Health

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

October 4, 2026 Evan Vega
HHS Expands Mental Health
Health

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

October 4, 2026 Evan Vega
Ebola Worker Evacuated Congo
Health

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

October 3, 2026 Evan Vega
Amivantamab approved for HNSCC
Health
November 7, 2026 Evan Vega

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

Read More
FDA approves Rybrevant Faspro
Health
November 7, 2026 Evan Vega

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

FDA grants accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.

Read More
FDA Approves Pirtobrutinib Treatment
Health
October 4, 2026 Evan Vega

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.

Read More
HHS Expands Mental Health
Health
October 4, 2026 Evan Vega

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

The U.S. HHS awarded $247.9 million in grants to expand mental health and addiction treatment services nationwide.

Read More
Ebola Worker Evacuated Congo
Health
October 3, 2026 Evan Vega

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

A Doctors Without Borders worker infected with Bundibugyo virus during DRC Ebola outbreak was evacuated to the Netherlands for specialized treatment.

Read More
FDA authorizes screwworm drugs
Health
September 16, 2026 Evan Vega

FDA issues emergency use authorization for drugs to prevent and treat New World screwworm in dogs and cats

The FDA authorized emergency use of Capstar and generic Nitenpyram to prevent and treat New World screwworm in dogs and cats nationwide.

Read More
FDA approves Alexander disease drug
Health
September 13, 2026 Evan Vega

FDA approves first drug to treat Alexander disease, offering a targeted therapy for the ultra-rare, progressive neurodegenerative disorder in children

The FDA approved Zanvastro, the first drug to treat Alexander disease by targeting abnormal GFAP buildup in pediatric and adult patients.

Read More
Listeria outbreak linked cheese
Health
September 13, 2026 Evan Vega

CDC and state health officials investigate multistate Listeria outbreak linked to soft-ripened cheese sold at Whole Foods Market, prompting nationwide recall and public warning to high-risk consumers

CDC and state officials investigated a 2013 multistate Listeria outbreak linked to Crave Brothers soft-ripened cheeses sold at Whole Foods, leading to a recall.

Read More
FDA approves oral dermatomyositis drug
Health
August 29, 2026 Evan Vega

FDA Approves Roivant’s Lisraya (brepocitinib) as First Oral Drug for Dermatomyositis

The FDA approved Roivant’s Lisraya (brepocitinib), the first oral dual TYK2/JAK1 inhibitor, to treat dermatomyositis in adults.

Read More
Herbal Supplements Contain Drugs
Health
August 28, 2026 Evan Vega

FDA Recalls 12 Herbal Supplements Over Hidden Drug Ingredients

GURU INC. recalled Infla-650 herbal supplement after FDA found undeclared drugs acetaminophen, diclofenac, and phenylbutazone in the capsules.

Read More
  • ← Previous
Copyright © 2026 DAILYZ HEALTH NEWS. Powered by ColorMag and WordPress.